Repeated Aerosolized AAV-CFTR for Treatment of Cystic Fibrosis: A Randomized Placebo-Controlled Phase 2B Trial
Richard B. Moss(Palo Alto University), Alison E. Heald(Targeted Medical Pharma (United States)), Henry L. Dorkin(Boston Children's Hospital), Dana B. Martin(Targeted Medical Pharma (United States)), Barrie J. Carter(Targeted Medical Pharma (United States)), Pamela L. Zeitlin(National Jewish Health), Mark Pian(University of San Diego), L. Terry Spencer(University of Florida), Thomas W. Ferkol(Washington University in St. Louis), John L. Colombo(University of Nebraska–Lincoln), Carlos Milla(Stanford University), John P. Clancy(Cystic Fibrosis Foundation), David A. Waltz(Boston Children's Hospital), Joseph M. Pilewski(University of Pittsburgh), Frank J. Accurso(University of Colorado Anschutz Medical Campus), Bonnie W. Ramsey(Seattle Children's Hospital)
Cited by 275
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1999|1.3k
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation
|New England Journal of Medicine|2010|802